ERBB2 and breast carcinoma: To the best of our knowledge, this multicenter phase II study is the first prospective study to explore the efficacy and safety of extended adjuvant pyrotinib after trastuzumab-based adjuvant therapy in patients with high-risk HER2-positive breast cancer.